The new management team of Redx Pharma is focusing its financial resources (ca.£10m) on progressing its lead candidates in oncology and fibrotic disease into the clinic. Although the first patient was treated recently in a Phase I/II proof-of-concept trial with its porcupine inhibitor RXC004, some on-target adverse events (anticipated at higher doses) were observed, which caused management to take the prudent decision to stop patient recruitment. A revised study with a lower dosing regimen is being prepared. Meanwhile, pre-clinical data on the synergy between RXC004 and a PD-1 checkpoint inhibitor in cancer was presented at AACR.
If you'd like to be introduced to the team at Redx Pharma, get in touch.Request a meeting